Public health
Thalidomide's second life in Indian leprosy
Open access · cc by · source: Europe PMC
Wimmelbücker and Kar show India’s thalidomide path ran through leprosy NGOs and delayed state control, not the 1960s sleeping-pill market of Europe.
Study at a glance
- Design
- Qualitative / archival — Documentary reconstruction of thalidomide’s Indian path via leprosy NGOs and delayed regulation
- N
- Archival/clinical/press sources (Grünenthal trials, WHO leprosy files); not a primary sample N
- Population
- Thalidomide importation, ENL trials, and regulation in India from the 1960s onward
- Outcome
- India’s thalidomide history through leprosy treatment rather than a 1960s hypnotic mass market
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
DCBL held Commonwealth rights including India, but the 1960s hypnotic market barely opened. After Sheskin, European mission doctors and WHO brought the drug for type-2 leprosy reactions in the country with the world’s largest leprosy population. Safety sat with doctors and the producer until 1986. No confirmed Indian embryopathy case is documented; surveillance remains weak as uses expand.
Methodology
The authors use Grünenthal trial documents, Israeli papers on Sheskin, WHO leprosy files, and published clinical and press sources—company archives still closed; Indian ministry and CLTRI holdings not then accessible—to track import, ENL trials after 1965, 1986 distribution responsibility, and 2002 approval for ENL and myeloma.
Limitations
Closed company and ministry archives limit the record. The 5000/3000 birth-defect figures refer to recognised cases in rich countries, not India. Absence of confirmed Indian cases is not proof of zero harm.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
What the archive does not hold shapes what can be said. The history of thalidomide in India was written with company archives still closed and Indian ministry and CLTRI holdings inaccessible, so the authors relied on Grünenthal trial documents, WHO leprosy files and published sources. They note that no confirmed Indian embryopathy case is documented, and that this absence is not proof of zero harm.
Evidence for the claim as stated.
Historians handle missing archives differently. The thalidomide-in-India study substitutes published clinical and press sources for closed company and ministry files and states the limits plainly. The onchocerciasis study fills gaps by combining archives with oral history and grey literature. Both approaches are legitimate but yield different kinds of certainty.
Evidence for the claim as stated.
Published clinical and press sources can substitute for closed archives. With Grünenthal's company archives closed and Indian ministry holdings inaccessible, the history of thalidomide in India was built partly from press and published sources, allowing the authors to trace leprosy uses and the 2002 approval while stating that the record remains limited.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Historians handle missing archives differently. The thalidomide-in-India study substitutes published clinical and press sources for closed company and ministry files and states the limits plainly. The onchocerciasis study fills gaps by combining archives with oral history and grey literature. Both approaches are legitimate but yield different kinds of certainty.
- Supports · How was river-blindness success built?
Related papers in this topic
Same topic cluster — not a recommendation engine.